Back to Search Start Over

Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: epitope definition and implications in risk stratification of patients under natalizumab therapy

Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: epitope definition and implications in risk stratification of patients under natalizumab therapy

Authors :
Diotti, Ra
Mancini, Nicasio
Clementi, Nicola
Sautto, G
Moreno, Gj
Criscuolo, E
Cappelletti, F
Man, P
Forest, E
Remy, L
Giannecchini, S
Clementi, Massimo
Burioni, Roberto
Criscuolo, Elena
Dipartimento di Scienze della Vita
Seconda Universita di Napoli
Laboratoire RMN des Matériaux Nanoporeux (FRE3230)
Université Pierre et Marie Curie - Paris 6 (UPMC)
Institut de biologie structurale (IBS - UMR 5075 )
Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG)
Direction de Recherche Fondamentale (CEA) (DRF (CEA))
Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA))
Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS)
Biotechnology
Fisica
Universita
INFN
Istituto Nazionale di Fisica Nucleare (INFN)
Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG)
Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)
Diotti, Ra
Mancini, Nicasio
Clementi, Nicola
Sautto, G
Moreno, Gj
Criscuolo, E
Cappelletti, F
Man, P
Forest, E
Remy, L
Giannecchini, S
Clementi, Massimo
Burioni, Roberto
Criscuolo, Elena
Thomas, Frank
Source :
Antiviral Research, Antiviral Research, Elsevier Masson, 2014, 108, pp.94-103, Antiviral Research, 2014, 108, pp.94-103
Publication Year :
2014
Publisher :
HAL CCSD, 2014.

Abstract

JC virus (JCPyV) has gained novel clinical importance as cause of progressive multifocal leukoencephalopathy (PML), a rare demyelinating disease recently associated to immunomodulatory drugs, such as natalizumab used in multiple sclerosis (MS) cases. Little is known about the mechanisms leading to PML, and this makes the need of PML risk stratification among natalizumab-treated patients very compelling. Clinical and laboratory-based risk-stratification markers have been proposed, one of these is represented by the JCPyV-seropositive status, which includes about 54% of MS patients. We recently proposed to investigate the possible protective role of neutralizing humoral immune response in preventing JCPyV reactivation. In this proof-of-concept study, by cloning the first human monoclonal antibody (GRE1) directed against a neutralizing epitope on JCPyV/VP1, we optimized a robust anti-JCPyV neutralization assay. This allowed us to evaluate the neutralizing activity in JCPyV-positive sera from MS patients, demonstrating the lack of correlation between the level of anti-JCPyV antibody and anti-JCPyV neutralizing activity. Relevant consequences may derive from future clinical studies induced by these findings; indeed the study of the serum anti-JCPyV neutralizing activity could allow not only a better risk stratification of the patients during natalizumab treatment, but also a better understanding of the pathophysiological mechanisms leading to PML, highlighting the contribution of peripheral versus central nervous system JCPyV reactivation. Noteworthy, the availability of GRE1 could allow the design of novel immunoprophylactic strategies during the immunomodulatory treatment.Copyright © 2014 Elsevier B.V. All rights reserved.

Details

Language :
English
ISSN :
01663542
Database :
OpenAIRE
Journal :
Antiviral Research, Antiviral Research, Elsevier Masson, 2014, 108, pp.94-103, Antiviral Research, 2014, 108, pp.94-103
Accession number :
edsair.doi.dedup.....f42364353db57dc7480dd7ab7c172837